Through 14 years of the BIEL stock being a sub-basement toilet dweller, for 6 or 7 outrageous reasons and lots of naysayers about a little company with an amazing product; is Synergy a ray of sunshine?
Obviously, there were protracted negotiations, both sides doing their jobs. I sense Keith Nalepka here, with Chairman Richard Staelin's wise leadership and Kelly Whelan simply staying quiet, as she should, and letting her thoroughbreds run. If I'm correct, she's listened and learned the essence of better management, than more than 10 years of - I don't know or care what others think. She's obviously reflected carefully.
BIEL would have negotiated for higher units, Synergy for lower units on the deal at hand. Obviously, both firms are optimistic, it's a business deal - sales and profits.. My question is a simple one. What if Synergy, in simply negotiating to hedge its exposure, turns out to be wrong by a couple of million units, or more and the units sold turns out to be 3 to 5 million, or more, for the 25 countries? Synergy is obviously a competent company, with serious ambitions.
Why do I ask, with a cautious, but an optimistic approach? Because the product is truly a 21st century miracle alternative to the many Billions of $$ spent on destructive drugs taken for aches and pains and healing globally, every year, all with much higher costs per treament hour and most with negative side-effects! BIEL does not give users free side-effects, ever! Its efficacy is certified by the FDA in an overwhelming majority of users and I'm sensing that Synergy's management gets it!
Thank you Keith, Richard and Kelly! Just don't be late fulfilling one order. Be early!
